SG11201802794PA - Therapeutic compounds and methods - Google Patents

Therapeutic compounds and methods

Info

Publication number
SG11201802794PA
SG11201802794PA SG11201802794PA SG11201802794PA SG11201802794PA SG 11201802794P A SG11201802794P A SG 11201802794PA SG 11201802794P A SG11201802794P A SG 11201802794PA SG 11201802794P A SG11201802794P A SG 11201802794PA SG 11201802794P A SG11201802794P A SG 11201802794PA
Authority
SG
Singapore
Prior art keywords
methods
therapeutic compounds
therapeutic
compounds
Prior art date
Application number
SG11201802794PA
Other languages
English (en)
Inventor
Daniel Vallera
Jeffrey Miller
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of SG11201802794PA publication Critical patent/SG11201802794PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201802794PA 2015-10-06 2016-10-06 Therapeutic compounds and methods SG11201802794PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562237835P 2015-10-06 2015-10-06
PCT/US2016/055722 WO2017062604A1 (fr) 2015-10-06 2016-10-06 Composés thérapeutiques et procédés

Publications (1)

Publication Number Publication Date
SG11201802794PA true SG11201802794PA (en) 2018-05-30

Family

ID=58488527

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201802794PA SG11201802794PA (en) 2015-10-06 2016-10-06 Therapeutic compounds and methods
SG10201912792YA SG10201912792YA (en) 2015-10-06 2016-10-06 Therapeutic compounds and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912792YA SG10201912792YA (en) 2015-10-06 2016-10-06 Therapeutic compounds and methods

Country Status (13)

Country Link
US (4) US11098100B2 (fr)
EP (2) EP3359168A4 (fr)
JP (3) JP7461620B2 (fr)
KR (1) KR20180057715A (fr)
CN (1) CN108697736A (fr)
AU (2) AU2016336451B2 (fr)
BR (1) BR112018006811A2 (fr)
CA (1) CA3001185A1 (fr)
IL (1) IL258931B (fr)
MX (1) MX2018004114A (fr)
RU (1) RU2770001C2 (fr)
SG (2) SG11201802794PA (fr)
WO (1) WO2017062604A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115029362A (zh) 2015-02-06 2022-09-09 新加坡国立大学 核酸、包含其的工程免疫细胞及其生产方法和用途
MX2018004114A (es) 2015-10-06 2018-08-21 Univ Minnesota Compuestos terapeuticos y metodos.
CA3016563A1 (fr) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Molecules multispecifiques et multifonctionnelles et leurs utilisations
BR112019002394B1 (pt) 2016-08-10 2021-12-21 Ajou University Industry-Academic Cooperation Foundation Proteína heterodimérica fundida com fc e seu uso
US20190038733A1 (en) 2017-08-10 2019-02-07 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
CA3085432A1 (fr) * 2017-12-12 2019-06-20 Macrogenics Inc. Derives de molecules de liaison a cd-16 bispecifiques et leur utilisation dans le traitement de maladies
CU24545B1 (es) * 2017-12-29 2021-09-07 Ct Ingenieria Genetica Biotecnologia Péptido antagonista de la actividad de la interleucina-15
JP7453971B2 (ja) * 2018-10-19 2024-03-21 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Ｎｋエンゲージャー分子およびその使用方法
CA3117212A1 (fr) 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Proteines heterodimeres fusionnees a un fragment fc
EP3976794A2 (fr) * 2019-05-31 2022-04-06 City of Hope Lymphocytes t modifiés par un récepteur antigénique chimérique ciblé sur cd33 pour le traitement de malignités positives cd33
AU2020290417A1 (en) * 2019-06-12 2022-01-06 The Board Of Trustees Of The Leland Stanford Junior University Methods to treat viral infections
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
KR20220087441A (ko) * 2019-09-16 2022-06-24 리젠츠 오브 더 유니버시티 오브 미네소타 면역요법 화합물 및 방법
CA3151281A1 (fr) * 2019-09-26 2021-04-01 Jeffrey S. Miller Composes d'engagement de cellules nk qui se lient a des antigenes viraux et procedes d'utilisation
EP4084821A4 (fr) * 2020-01-03 2024-04-24 Marengo Therapeutics Inc Molécules multifonctionnelles se liant à cd33 et utilisations associées
KR20230004746A (ko) 2020-04-22 2023-01-06 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체 fc-융합 단백질에 대한 제형, 투여 요법 및 제조 방법
BR112022024768A2 (pt) * 2020-06-03 2022-12-27 Univ Minnesota Proteínas de alvejamento a b7h3 e métodos de uso das mesmas
WO2022150379A1 (fr) * 2021-01-08 2022-07-14 Regents Of The University Of Minnesota Molécules de mise en contact de cellules nk et méthodes d'utilisation
CN116574190A (zh) 2021-07-30 2023-08-11 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
WO2023036270A1 (fr) 2021-09-09 2023-03-16 启愈生物技术(上海)有限公司 Ciblage d'antigène, anti-cd16a et protéine de fusion fonctionnelle d'activation de cellule effectrice immunitaire, et son utilisation
WO2023225531A2 (fr) * 2022-05-16 2023-11-23 Northwestern University Lymphocytes t de car modifiées d'il15 pour double ciblage
WO2023232911A1 (fr) * 2022-05-31 2023-12-07 Oncopeptides Innovation 1 Ab Nouveaux polypeptides
WO2024056862A1 (fr) 2022-09-15 2024-03-21 Avidicure Ip B.V. Protéines multispécifiques de liaison à l'antigène pour le ciblage tumoral de cellules nk et leur utilisation
WO2024064446A2 (fr) * 2022-09-19 2024-03-28 Duke University Compositions et méthodes permettant l'amélioration d'activités de cellules immunitaires contre le cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515750A (ja) 2002-12-20 2006-06-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多価リンホトキシンβレセプターアゴニストおよびそれを使用する治療
KR20050094819A (ko) 2002-12-20 2005-09-28 바이오겐 아이덱 엠에이 인코포레이티드 화학요법제와 조합된 림프독소 베타 수용체 약제
HUE033129T2 (en) 2003-07-24 2017-11-28 Innate Pharma Sa Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells
NZ544448A (en) 2004-03-19 2009-10-30 Morinaga Milk Industry Co Ltd Medicine for cancer therapy containing a lactoferrin hydrolysate and antibody
WO2006099141A2 (fr) 2005-03-10 2006-09-21 Morphotek, Inc. Anticorps diriges contre la mesotheline
US8993295B2 (en) * 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
CN101657719A (zh) 2007-01-26 2010-02-24 路易斯维尔大学研究基金会公司 检测用于诊断和表征障碍的自身抗体的方法
EP2197909A4 (fr) * 2007-08-24 2014-12-03 Univ Minnesota Réactifs de ciblage de récepteurs
EP2332994A1 (fr) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Thérapie trispécifique contre la leucémie myéloïde aiguë
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012017522A1 (fr) 2010-08-03 2012-02-09 富士通株式会社 Programme de vérification et dispositif de vérification
PT2619229T (pt) * 2010-09-21 2016-07-13 Altor Bioscience Corp Moléculas de fusão de il-15 multiméricas solúveis e métodos de produção e utilização das mesmas
CN102251013A (zh) 2011-02-22 2011-11-23 北京市肿瘤防治研究所 一个识别肿瘤起始细胞的抗体和抗原及其应用
PT2714735T (pt) 2011-06-03 2021-10-26 Xoma Technology Ltd Anticorpos específicos para tgf-beta
EP2537933A1 (fr) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
WO2013039883A1 (fr) 2011-09-12 2013-03-21 Abbvie Biotherapeutics Inc. Cellules nk artificielles et utilisation de celles-ci
WO2013163427A1 (fr) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps pour traiter les infections par le vih-1
US9258177B2 (en) * 2012-08-02 2016-02-09 International Business Machines Corporation Storing a data stream in a set of storage devices
WO2014138306A1 (fr) * 2013-03-05 2014-09-12 Baylor College Of Medicine Cellules d'engagement pour immunothérapie
US9879081B2 (en) * 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
JP6793902B2 (ja) 2013-12-20 2020-12-02 ノバルティス アーゲー 調節可能キメラ抗原受容体
MX2018004114A (es) 2015-10-06 2018-08-21 Univ Minnesota Compuestos terapeuticos y metodos.

Also Published As

Publication number Publication date
RU2770001C2 (ru) 2022-04-14
RU2018116565A (ru) 2019-11-07
JP2022037037A (ja) 2022-03-08
IL258931A (en) 2018-06-28
JP7274781B2 (ja) 2023-05-17
US20180282386A1 (en) 2018-10-04
AU2016336451B2 (en) 2023-06-29
BR112018006811A2 (pt) 2018-10-16
EP3359168A4 (fr) 2019-08-07
JP2018531939A (ja) 2018-11-01
US20210395326A1 (en) 2021-12-23
MX2018004114A (es) 2018-08-21
IL258931B (en) 2022-09-01
CN108697736A (zh) 2018-10-23
CA3001185A1 (fr) 2017-04-13
AU2023233318A1 (en) 2023-10-12
AU2016336451A1 (en) 2018-04-26
EP4056190A1 (fr) 2022-09-14
JP7461620B2 (ja) 2024-04-04
US20200087369A1 (en) 2020-03-19
US11098100B2 (en) 2021-08-24
US11098101B2 (en) 2021-08-24
SG10201912792YA (en) 2020-02-27
EP3359168A1 (fr) 2018-08-15
KR20180057715A (ko) 2018-05-30
US20200148737A1 (en) 2020-05-14
WO2017062604A1 (fr) 2017-04-13
JP2023089290A (ja) 2023-06-27
RU2018116565A3 (fr) 2020-11-03

Similar Documents

Publication Publication Date Title
IL258931A (en) Medicinal compounds and methods
HK1256383A1 (zh) 治療劑
HK1247614A1 (zh) 治療化合物及其用途
ZA201804070B (en) Eif4-a-inhibiting compounds and methods related thereto
HK1243073A1 (zh) 治療性化合物及其用途
GB201403093D0 (en) Therapeutic compounds and their use
GB201509893D0 (en) Therapeutic agents
GB201517263D0 (en) Therapeutic agents
HK1248697A1 (zh) 治療化合物及其用途
ZA201802256B (en) Compounds and therapeutic uses thereof
GB201609597D0 (en) Therapy
GB201502412D0 (en) Therapeutic use
GB201509885D0 (en) Therapeutic agents
IL247325A0 (en) Therapeutic methods using noribogaine and related compounds
GB201509888D0 (en) Therapeutic agents
IL270011B (en) Medicinal compounds and methods
GB201513299D0 (en) Therapeutic agents
GB201521767D0 (en) Therapeutic agents
GB201517264D0 (en) Therapeutic agents
GB201506786D0 (en) Therapeutic use
GB201618477D0 (en) Therapy
GB201615923D0 (en) Macrophage-based therapy
GB201609721D0 (en) Cobination therapy
GB201609312D0 (en) Therapy
GB201609322D0 (en) Therapy